A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: Durvalumab|DRUG: Capivasertib|DRUG: Oleclumab|DRUG: Paclitaxel|DRUG: Trastuzumab deruxtecan|DRUG: Datopotamab deruxtecan
Sponsor: AstraZeneca